OZEMPIC
Clinical safety rating
cautionComprehensive clinical and safety monograph for OZEMPIC (OZEMPIC).
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the action of endogenous GLP-1, which increases insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety. The primary mechanism is activation of GLP-1 receptors on pancreatic beta cells, leading to glucose-dependent insulin release.
| Metabolism | Semaglutide is metabolized via proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain. No specific CYP450 enzymes are involved. |
| Excretion | Primarily renal (80%) and biliary/fecal (20%). Unchanged parent drug accounts for ~5-10%; majority is degraded into small peptides/amino acids. |
| Half-life | Terminal elimination half-life approximately 1 week (5–7 days) in subcutaneous dosing, allowing once-weekly administration. Steady state reached after 4–5 weeks. |
| Protein binding | >99% bound to albumin. |
| Volume of Distribution | Approximately 0.12 L/kg (mean ~8.3 L), indicating limited extravascular distribution and confinement primarily to plasma and interstitial fluid. |
| Bioavailability | Subcutaneous: 89% (95% CI: 80–97%). Not orally bioavailable due to peptide degradation. |
| Onset of Action | Subcutaneous: Glycemic effects begin within 2–3 weeks; maximal glucose-lowering effect by 8 weeks. Dose-dependent delay in gastric emptying occurs within first dose. |
| Duration of Action | Pharmacodynamic effects last approximately 1 week (7 days) after a single subcutaneous dose, supporting once-weekly dosing. Gastric emptying effects persist for 12–16 hours per dose. |
| Molecular Weight | 4113.6 |
| Action Class | GLP-1 Receptor Agonist |
1 mg subcutaneously once weekly, starting at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly for at least 4 weeks before escalating to 1 mg.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR 30-89 mL/min. Avoid use if GFR < 30 mL/min due to limited data and potential for gastrointestinal adverse effects. |
| Liver impairment | No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Not approved for pediatric patients; no established dosing guidelines. |
| Geriatric use | No specific dose adjustment needed based on age; monitor renal function due to age-related decline and consider cautious titration due to increased risk of gastrointestinal effects and dehydration. |
| 1st trimester | Semaglutide is contraindicated in pregnancy; based on animal studies, there is evidence of fetal risk. Conception should be avoided during therapy and for at least 2 months after discontinuation. |
| 2nd trimester | Contraindicated; potential fetal harm. No adequate human studies. |
| 3rd trimester | Contraindicated; risk of neonatal hypoglycemia and congenital anomalies. |
Clinical note
Comprehensive clinical and safety monograph for OZEMPIC (OZEMPIC).
| Placental transfer | Anticipated to cross placenta due to molecular properties; animal studies show fetal exposure. |
| Breastfeeding | Not recommended; semaglutide is excreted in rat milk, but no human data. Potential adverse effects on nursing infant. |
| Lactation Rating | L5 |
| Teratogenic Risk | No adequate human studies. Animal studies show fetal growth retardation, skeletal anomalies, and increased pregnancy loss at exposures similar to human exposure. Risk cannot be excluded in first trimester. Second and third trimester: potential for fetal pancreatic beta-cell hyperplasia and altered glucose homeostasis. |
| Fetal Monitoring | Monitor blood glucose, HbA1c, and weight. Ultrasound for fetal growth and amniotic fluid volume. Monitor for maternal gastrointestinal adverse effects (nausea, vomiting) that may affect hydration and electrolyte balance. |
| Fertility Effects | In animal studies, no adverse effects on fertility. No human data; theoretical risk based on effect on body weight and metabolism. |
■ FDA Black Box Warning
No FDA black box warning exists for Ozempic.
| Common Effects | Nausea, Vomiting, Diarrhea, Abdominal pain, Decreased appetite, Constipation, Dyspepsia, Fatigue, Dizziness, Headache |
| Serious Effects | Pancreatitis (acute or chronic), Medullary thyroid carcinoma (C-cell tumors, seen in animal studies; contraindicated in patients with personal/family history of MTC or MEN-2), Diabetic retinopathy complications (especially in patients with history of retinopathy), Acute kidney injury or worsening of chronic renal failure, Severe gastrointestinal adverse reactions (e.g., gastroparesis, ileus), Hypersensitivity reactions (e.g., anaphylaxis, angioedema), Cholelithiasis and cholecystitis |
Personal or family history of medullary thyroid carcinoma (MTC)Multiple endocrine neoplasia syndrome type 2 (MEN-2)PregnancyHypersensitivity to semaglutide or any excipients
| Precautions | Risk of thyroid C-cell tumors: Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)., Acute pancreatitis: Discontinue if suspected., Diabetic retinopathy complications: Increased risk, especially in patients with a history of retinopathy., Hypoglycemia: Increased risk when used with insulin or insulin secretagogues., Renal impairment: Acute kidney injury reported; monitor renal function., Gastrointestinal effects: Nausea, vomiting, diarrhea; may cause volume depletion., Hypersensitivity: Serious allergic reactions reported. |
| Food/Dietary | No specific food interactions. Ozempic delays gastric emptying, which may affect absorption of oral medications. Take oral medications requiring rapid absorption (e.g., antibiotics, oral contraceptives) at least 1 hour before Ozempic injection. No dietary restrictions required, but nausea may be reduced by eating smaller, less fatty meals. |
| Clinical Pearls | Ozempic (semaglutide) is a GLP-1 receptor agonist for type 2 diabetes. Start at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg. If additional glycemic control needed, may increase to 1 mg after at least 4 weeks. Administer subcutaneously once weekly, any time of day, with or without meals. Missed dose: if >5 days late, skip and resume next scheduled dose. Common side effects: nausea, vomiting, diarrhea, constipation. Risk of hypoglycemia when used with insulin or sulfonylureas; consider dose reduction of these agents. Contraindicated in medullary thyroid carcinoma (MTC) personal/family history or MEN-2. Monitor for pancreatitis and acute kidney injury. May delay gastric emptying; caution with oral medications requiring rapid absorption. Not first-line for weight loss but may promote significant weight reduction. |
| Patient Advice | Inject Ozempic once a week on the same day, any time of day, with or without food. · Do not share pens even if needle changed; risk of infection transmission. · Store unused pens in refrigerator (36°F to 46°F); in-use pen can be stored at room temperature (59°F to 86°F) for up to 56 days. · Rotate injection sites (abdomen, thigh, upper arm) to avoid lipodystrophy. · Report persistent severe abdominal pain (possible pancreatitis) or vision changes (possible diabetic retinopathy complications). · If you miss a dose, take it within 5 days of missed dose; if more than 5 days, skip and resume next scheduled dose. · Take oral medications at least 1 hour before Ozempic injection if delayed gastric emptying is a concern. · Do not drive or operate machinery until you know how Ozempic affects you, as dizziness may occur. · Carry a fast-acting sugar source (e.g., glucose tablets) if also using insulin or sulfonylureas. · Weight loss is possible but not the primary FDA-approved indication; discuss weight management goals with your provider. |
Loading safety data…